MENU

Lonvo-z: Intellia’s in vivo CRISPR therapy and FDA timeline

Nature(News) USA
Overview
Intellia Therapeutics has applied for FDA approval of lonvoguran ziclumeran (lonvo-z), a CRISPR-Cas9 therapy that edits genes directly inside the body. Data shows the treatment remains effective four years post-administration, potentially eliminating the need for lifelong medication for hereditary angioedema.
In Depth

Key Findings

Intellia Therapeutics has submitted an application to the US Food and Drug Administration (FDA) for lonvoguran ziclumeran (lonvo-z). If approved, lonvo-z will be the first CRISPR-based medicine delivered in vivo (directly inside the body). A decision from the FDA is expected by 10 March. Recent data released by the developer indicates that the therapy continues to be effective four years after treatment.

Technical Details

Lonvo-z is designed to treat a form of hereditary angioedema characterized by painful swelling in the throat and other body parts. The therapy utilizes the CRISPR–Cas9 system to disable the gene responsible for producing prekallikrein, a liver-produced protein that promotes blood-vessel leakage. To achieve this, the therapy employs fatty particles that encase mRNA encoding the CRISPR–Cas9 components. These particles are infused into the blood and taken up by the liver. The entire procedure takes one day.

Background & Context

Currently, the only FDA-approved CRISPR therapy is Casgevy, used for sickle-cell disease and β-thalassaemia. Unlike lonvo-z, Casgevy is an ex vivo treatment: blood stem cells are removed from the patient, edited externally, and then re-infused. This process requires harsh chemotherapy to prepare the patient’s body and involves higher costs and complexity because each dose must be custom-made for the individual.

Significance & Outlook

The transition to in vivo editing aims to sidestep the complexities of cell removal and chemotherapy. However, this approach introduces specific safety risks, including the inability to screen for unwanted off-target edits and the potential for harmful immune responses. Intellia previously faced a clinical hold on two other in vivo trials after a participant with additional health conditions died from liver damage; the FDA lifted this hold this year following the implementation of extra safety measures.

]]

Source: https://www.nature.com/articles/d41586-026-03705-9

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC